Performance of early pregnancy HbA1c for predicting gestational diabetes mellitus and adverse pregnancy outcomes in obese European women
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Performance of early pregnancy HbA1c for predicting gestational diabetes mellitus and adverse pregnancy outcomes in obese European women. / Immanuel, Jincy; Simmons, David; Desoye, Gernot; Corcoy, Rosa; Adelantado, Juan M.; Devlieger, Roland; Lapolla, Annunziata; Dalfra, Maria G.; Bertolotto, Alessandra; Harreiter, Jürgen; Wender-Ozegowska, Ewa; Zawiejska, Agnieszka; Dunne, Fidelma P.; Damm, Peter; Mathiesen, Elisabeth R.; Jensen, Dorte M.; Andersen, Lise Lotte T.; Hill, David J.; Jelsma, Judith G.M.; Snoek, Frank J.; Scharnagl, Hubert; Galjaard, Sander; Kautzky-Willer, Alexandra; VAN Poppel, Mireille N.M.
In: Diabetes Research and Clinical Practice, Vol. 168, 108378, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Performance of early pregnancy HbA1c for predicting gestational diabetes mellitus and adverse pregnancy outcomes in obese European women
AU - Immanuel, Jincy
AU - Simmons, David
AU - Desoye, Gernot
AU - Corcoy, Rosa
AU - Adelantado, Juan M.
AU - Devlieger, Roland
AU - Lapolla, Annunziata
AU - Dalfra, Maria G.
AU - Bertolotto, Alessandra
AU - Harreiter, Jürgen
AU - Wender-Ozegowska, Ewa
AU - Zawiejska, Agnieszka
AU - Dunne, Fidelma P.
AU - Damm, Peter
AU - Mathiesen, Elisabeth R.
AU - Jensen, Dorte M.
AU - Andersen, Lise Lotte T.
AU - Hill, David J.
AU - Jelsma, Judith G.M.
AU - Snoek, Frank J.
AU - Scharnagl, Hubert
AU - Galjaard, Sander
AU - Kautzky-Willer, Alexandra
AU - VAN Poppel, Mireille N.M.
PY - 2020
Y1 - 2020
N2 - Aims: To investigate the performance of early pregnancy HbA1c for predicting gestational diabetes mellitus (GDM) and adverse pregnancy outcomes in obese women. Methods: Post hoc analysis using data from the Vitamin D And Lifestyle Intervention for GDM prevention trials conducted across 9 European countries (2012–2014). Pregnant women (BMI ≥ 29 kg/m2) underwent a baseline HbA1c and oral glucose tolerance tests at < 20 weeks, 24–28 weeks, and 35–37 weeks. Women with GDM were referred for treatment. Results: Among the 869 women tested, the prevalence of GDM was 25.9% before 20 weeks, with a further 8.6% at 24–28 weeks. The areas under the curves for HbA1c at the two time points were 0.55 (0.50–0.59) and 0.54 (0.47–0.61), respectively. An early HbA1c ≥ 5.7% (39 mmol/mol) (N = 111) showed low sensitivity (18.2%) with 89.1% specificity for GDM before 20 weeks, at 24–28 weeks (sensitivity of 8.0% and specificity of 88.6% after excluding early GDM), and throughout gestation (sensitivity of 15.9% and specificity of 89.4%). The ≥ 5.7% (39 mmol/mol) threshold was significantly associated with concurrent GDM before 20 weeks (adjusted OR (aOR) 2.77(1.39–5.51)) and throughout gestation (aOR 1.72 (1.02–2.89)), but not adverse pregnancy outcomes. Conclusions: Early pregnancy HbA1c is of limited use for predicting either GDM or adverse outcomes in overweight/obese European women.
AB - Aims: To investigate the performance of early pregnancy HbA1c for predicting gestational diabetes mellitus (GDM) and adverse pregnancy outcomes in obese women. Methods: Post hoc analysis using data from the Vitamin D And Lifestyle Intervention for GDM prevention trials conducted across 9 European countries (2012–2014). Pregnant women (BMI ≥ 29 kg/m2) underwent a baseline HbA1c and oral glucose tolerance tests at < 20 weeks, 24–28 weeks, and 35–37 weeks. Women with GDM were referred for treatment. Results: Among the 869 women tested, the prevalence of GDM was 25.9% before 20 weeks, with a further 8.6% at 24–28 weeks. The areas under the curves for HbA1c at the two time points were 0.55 (0.50–0.59) and 0.54 (0.47–0.61), respectively. An early HbA1c ≥ 5.7% (39 mmol/mol) (N = 111) showed low sensitivity (18.2%) with 89.1% specificity for GDM before 20 weeks, at 24–28 weeks (sensitivity of 8.0% and specificity of 88.6% after excluding early GDM), and throughout gestation (sensitivity of 15.9% and specificity of 89.4%). The ≥ 5.7% (39 mmol/mol) threshold was significantly associated with concurrent GDM before 20 weeks (adjusted OR (aOR) 2.77(1.39–5.51)) and throughout gestation (aOR 1.72 (1.02–2.89)), but not adverse pregnancy outcomes. Conclusions: Early pregnancy HbA1c is of limited use for predicting either GDM or adverse outcomes in overweight/obese European women.
KW - Diagnostic threshold
KW - Gestational diabetes mellitus
KW - Hemoglobin A
KW - Odds Ratio
KW - Pregnancy
KW - Pregnancy outcome
U2 - 10.1016/j.diabres.2020.108378
DO - 10.1016/j.diabres.2020.108378
M3 - Journal article
C2 - 32828833
AN - SCOPUS:85090030724
VL - 168
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
M1 - 108378
ER -
ID: 250383457